Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258335 · ClinicalTrials.gov registry record · NA
Omega-3-fatty Acids on Age-related Macular
A NA study of Aged Macular Degeneration, sponsored by Mid Atlantic Retina.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01258335: Completed NA study of Aged Macular Degeneration, sponsored by Mid Atlantic Retina.
NCT01258335 is a NA study of Aged Macular Degeneration that has completed, run by Mid Atlantic Retina. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01258335, a NA study of Aged Macular Degeneration, has completed, sponsored by Mid Atlantic Retina.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD). Null hypothesis: Omega-3-fatty acids do not affect the mfERGs of patients with dry AMD.
Primary Outcome
Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD). Null hypothesis: Omega-3-fatty acids do not affect the mfERGs of patients with dry AMD.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Omega 3
- OTHER Olive Oil
Study Locations (1)
Pennsylvania
- Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-11 |
| Phase | NA |
What the finished NCT01258335 record still lists
NCT01258335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aged Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Omega 3 is the first listed.
NCT01258335 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01258335 about?
NCT01258335 is a clinical study titled "Omega-3-fatty Acids on Age-related Macular". Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD). Null hypothesis: Omega-3-fatty acids do not affect the mfERGs of patients with dry AMD.
What is the current status of trial NCT01258335?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2008-10. Estimated completion is 2010-11.
What conditions does trial NCT01258335 study?
This clinical trial studies the following conditions: Aged Macular Degeneration.
What interventions are being tested in trial NCT01258335?
The interventions under investigation include: Omega 3 (DIETARY_SUPPLEMENT), Olive Oil (OTHER).
Who is sponsoring clinical trial NCT01258335?
This trial is sponsored by Mid Atlantic Retina, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01258335 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01258335's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia